Lantheus shares fell 25% post-Q1 2025 report due to disappointing EPS guidance and not meet analysts' expectations. EPS reduction was driven by flat PYLARIFY sales and changes in Medicare coverage, impacting profitability and gross margins. Strategic transformation includes divesting the low-margin SPECT segment and acquiring LMI and Evergreen to expand into lucrative Alzheimer's and cancer dia...
Investors searching for high-quality opportunities in the pharmaceutical space should keep a close eye on stocks trading at extremely oversold levels. One of the most popular ways to measure this is through the Relative Strength Index (RSI), a technical momentum indicator that signals when a stock may be due for a rebound.
LOS ANGELES , May 8, 2025 /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of Lantheus Holdings, Inc. ("Lantheus" or "the Company") (NASDAQ: LNTH) for violations of the securities laws. INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and/or failed to disclose information pertinent to investors.
LOS ANGELES--(BUSINESS WIRE)--Lantheus Holdings, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - LNTH.
Enables Lantheus to focus on innovative radiopharmaceuticals, while maximizing the value of its SPECT business SHINE will acquire products TechneLite®, NEUROLITE®, Xenon Xe-133 Gas, and Cardiolite® BEDFORD, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company dedicated to helping clinicians ...
BEDFORD, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that its clinical-stage F18-labeled tau Positron Emission Tomography (PET) radiodiagnostic, MK-6240 (F18-florquinitau), succes...
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.